GE HealthCare (GEHC)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$68.86-1.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Revenue growth to about $4.9 billion per share in 2026: FY26 revenue growth guidance 3.0-4.0% vs trip condition <5.7%.
GE HealthCare aims to grow revenue and improve profit margins. It targets about $4.9 billion revenue per share in 2026. The company plans profit margins near 16% in 2026. Cash flow remains a focus with a $1.6 billion target for 2026.
Revenue and profit fell recently, showing trouble growing the business. Cash flow is uneven and operating income dropped from $827M to $515M. The company faces challenges meeting its goals and improving profits.
The price is about 21% below our fair value near $82. Analysts expect about 6% revenue growth. Our view aligns with the Street on growth but sees risks in profit and cash flow.
Breaks if: Free cash flow falls below $1.4 billion next year
Breaks if: Operating margin falls below 15% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on steady growth. The current thesis state is intact, supported by strong recent financial performance despite some volatility in management and potential sector challenges.
The market currently prices GEHC as cheap compared to its peers, with a slight expectations gap indicating that some cautious sentiment is already reflected. There is a low fragility tier, suggesting that the stock is not overly sensitive to negative news at this time.
Management has reaffirmed its goals for organic revenue growth and cash flow generation, showing a strong commitment to these targets. However, the adjusted EBIT margin expansion is behind schedule, which may impact overall performance if not addressed.
The long-term thesis hinges on management's ability to deliver on growth targets and improve margins. Additionally, the performance of sector peers and broader economic indicators, such as job reports, will be crucial in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this view. GE HealthCare secured a CE mark for its Photonova Spectra CT system. This advance boosts innovation and commercial growth in Pharmaceutical Diagnostics. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on improving operating income through cost management and efficiency.
Breaks if: Revenue growth falls below ~5.7% next year
Over the next 1 to 3 years, GEHC's performance will depend on effective management execution and external economic conditions. Not investment advice.